The profound change in growth characteristics of tumor cells caused by loss of FOXD1 makes it an attractive therapeutic target, and since there is no reported strategy to inactivate FOXD1 itself, our work focused on the downstream pathways that are targetable. The gene discussed is FOXD1; the disease is neoplasm.